Status:
UNKNOWN
Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism
Lead Sponsor:
Université Catholique de Louvain
Conditions:
Kidney Diseases
Eligibility:
All Genders
15-70 years
Phase:
PHASE4
Brief Summary
To optimize the Advagraf (tacrolimus once a day) initial daily dose used in de novo after kidney transplantation in combination with MMF (or MPA) and corticosteroids (CS) regarding of the genetic Cyp ...
Eligibility Criteria
Inclusion
- First or second Kidney Transplantation from deceased or living donor
Exclusion
- Donor age \< 5 years.
- Patients who require plasma exchange because of high immunological risk
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2015
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT02311010
Start Date
January 1 2011
End Date
January 1 2015
Last Update
December 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cliniques universitaires Saint Luc Université Catholique de Louvain
Brussels, Belgium, 1200